Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant.
All Keywords
【저자키워드】 SARS-CoV-2, B.1.617.2, vaccine effectiveness,: COVID-19 Vaccines, Norway, Delta variant of concern, 【초록키워드】 Vaccine, disease severity, hospital, Infection, delta variant, cohort study, Laboratory, Transmissibility, Effectiveness, Alpha, Alpha variant, population-based cohort, 95% CI, 95% confidence interval, vaccinated individuals, variants of SARS-CoV-2, individuals, 【제목키워드】 variant, Infection, Delta, Effectiveness,
【저자키워드】 SARS-CoV-2, B.1.617.2, vaccine effectiveness,
SARS-CoV-2의 일부 변이체는 전염성 증가, 질병 중증도 증가 또는 백신 효과 감소(VE)와 관련이 있습니다. 이 인구 기반 코호트 연구(n=4,204,859)에서 Delta 변이는 5,430명(0.13%)에서 확인되었으며 이 중 84명이 병원에 입원했습니다. Delta 변이체로 실험실에서 확인된 감염에 대한 VE는 부분 백신 접종(95% 신뢰 구간(CI): 17.0-27.4) 사이에서 22.4%, 완전 백신 접종을 받은 개체에서 64.6%(95% CI: 60.6-68.2), 54.5%( 알파 변이체에 대해 95% CI: 50.4-58.3) 및 84.4%(95%CI: 81.8-86.5).